A photo of Carolyn Lutzko.

Carolyn M. Lutzko, PhD


  • Director, Cell Manipulation Laboratory and Translational Research and Development, Translational Core Laboratory
  • Division Director, Regenerative Medicine and Cellular Therapies, Hoxworth Blood Center
  • Associate Professor, UC Department of Pediatrics

About

Publications

Selected

Integrated Genomic Analysis of Diverse Induced Pluripotent Stem Cells from the Progenitor Cell Biology Consortium. Salomonis, N; Dexheimer, PJ; Omberg, L; Schroll, R; Bush, S; Huo, J; Schriml, L; Sui, SH; Keddache, M; Mayhew, C; et al. Stem Cell Reports. 2016; 7:110-125.

Selected

Pathogenesis of ELANE-mutant severe neutropenia revealed by induced pluripotent stem cells. Nayak, RC; Trump, LR; Aronow, BJ; Myers, K; Mehta, P; Kalfa, T; Wellendorf, AM; Valencia, CA; Paddison, PJ; Horwitz, MS; et al. Journal of Clinical Investigation. 2015; 125:3103-3116.

Off-the-Shelf Third-Party Virus-Specific T Cell Therapy to Treat JC Polyomavirus Infection in Hematopoietic Stem Cell Transplantation Recipients. Rubinstein, JD; Jodele, S; Heyenbruch, D; Wilhelm, J; Thomas, S; Lutzko, C; Zhu, X; Leemhuis, T; Cancelas, JA; Keller, M; et al. Transplantation and cellular therapy. 2021.

SERF1 Is Required for G-CSF Resistance of Start-Codon Mutant ELANE Granulocytic Precursors. Nayak, RC; Trump, L; Emberesh, S; Lee, Y; Singh, AK; Wellendorf, AM; Horwitz, MS; Kalfa, TA; Lutzko, C; Cancelas, JA. Blood. 2021; 138:433-433.

Safety and Efficacy of Aru-1801 in Patients with Sickle Cell Disease: Early Results from the Phase 1/2 Momentum Study of a Modified Gamma Globin Gene Therapy and Reduced Intensity Conditioning. Grimley, M; Asnani, M; Shrestha, A; Felker, S; Lutzko, C; Arumugam, PI; Witting, S; Knight-Madden, J; Niss, O; Quinn, CT; et al. Blood. 2021; 138:3970-3970.

Virus-specific T cells for adenovirus infection after stem cell transplantation are highly effective and class II HLA restricted. Rubinstein, JD; Zhu, X; Leemhuis, T; Pham, G; Ray, L; Emberesh, S; Jodele, S; Thomas, S; Cancelas, JA; Bollard, CM; et al. Blood Advances. 2021; 5:3309-3321.

Congenital dyserythropoietic anemia type I: First report from the Congenital Dyserythropoietic Anemia Registry of North America (CDAR). Niss, O; Lorsbach, RB; Berger, M; Chonat, S; McLemore, M; Buchbinder, D; McCavit, T; Shaffer, LG; Simpson, J; Schwartz, JH; et al. Blood Cells, Molecules, and Diseases. 2021; 87.

The Natural History of BK Polyomavirus and the Host Immune Response After Stem Cell Transplantation. Laskin, BL; Denburg, MR; Furth, SL; Moatz, T; Altrich, M; Kleiboeker, S; Lutzko, C; Zhu, X; Blackard, JT; Jodele, S; et al. Clinical Infectious Diseases. 2020; 71:3044-3054.

VPS4A Mutations in Humans Cause Syndromic Congenital Dyserythropoietic Anemia due to Cytokinesis and Trafficking Defects. Seu, KG; Trump, LR; Emberesh, S; Lorsbach, RB; Johnson, C; Meznarich, J; Underhill, HR; Chou, ST; Sakthivel, H; Nassar, NN; et al. American Journal of Human Genetics. 2020; 107:1149-1156.

Virus-specific T-cell therapy to treat BK polyomavirus infection in bone marrow and solid organ transplant recipients. Nelson, AS; Heyenbruch, D; Rubinstein, JD; Sabulski, A; Jodele, S; Thomas, S; Lutzko, C; Zhu, X; Leemhuis, T; Cancelas, JA; et al. Blood Advances. 2020; 4:5745-5754.

From the Blog


Highlighting Heroes: Turnaround Enables COVID-19 Testing for Employees and Patients
Infectious Diseases and Vaccines

Highlighting Heroes: Turnaround Enables COVID-19 Testing for Employees and Patients

Carolyn M. Lutzko, PhD4/2/2020